Loading clinical trials...

A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease | Clinical Trials | Clareo Health

WITHDRAWNNANCT00469625

A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease

Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney disease in the United States. The degree of proteinuria is associated with risk for renal disease progression an...

Lead sponsor: Winthrop University Hospital•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

Not Yet RecruitingPhase 1

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

NCT07224776 · Proteinuric Renal Disease, Proteinuric Kidney Disease, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 28, 2015Terms

Trial snapshot

StatusWITHDRAWN

PhaseNA

Enrollment—

Start dateJul 2006

Last updatedDec 28, 2015

Condition

Proteinuric Renal Disease

Locations shown

Winthrop Univ. Hospital

Mineola, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 28, 2015Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions